Unicancer GI PRODIGE 24/CCTG PA.6 trial: A multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas.

被引：110

作者：

Conroy, Thierry

Hammel, Pascal

Hebbar, Mohamed

Ben Abdelghani, Meher

Wei, Alice Chia-chi

Raoul, Jean-Luc

Chone, Laurence

Francois, Eric

Artru, Pascal

Biagi, James Joseph

Lecomte, Thierry

Assenat, Eric

Faroux, Roger

Ychou, Marc

Volet, Julien

Sauvanet, Alain

Jouffroy-Zeller, Claire

Rat, Patrick

Castan, Florence

Bachet, Jean-Baptiste

机构：

[1] Inst Cancerol Lorraine, Vandoeuvre Les Nancy, France

[2] Hop Beaujon, Clichy, France

[3] Hop Huriez, Lille, France

[4] Ctr Paul Strauss, Strasbourg, France

[5] Princess Margaret Canc Ctr, Toronto, ON, Canada

[6] Inst Paoli Calmettes, Marseille, France

[7] Ctr Hosp Univ, Nancy, France

[8] Ctr Antoine Lacassagne, Nice, France

[9] Hop Prive Jean Mermoz, Lyon, France

[10] Kingston Gen Hosp, Canc Ctr SE Ontario, Kingston, ON, Canada

[11] Hop Trousseau, Tours, France

[12] Hop St Eloi, Montpellier, France

[13] CHD Vendee, La Roche Sur Yon, France

[14] Montpellier Canc Inst, Montpellier, France

[15] Ctr Hosp Reims Robert Debre, Reims, France

[16] Unicancer, Paris, France

[17] CHU Dijon, Dijon, France

[18] Inst Canc Montpellier, Biometr Dept, Montpellier, France

[19] Hosp Pitie Salpetriere, Paris, France

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 18期

关键词：

D O I：

10.1200/JCO.2018.36.18_suppl.LBA4001

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA4001

引用

页数：1